Idexx Laboratories
IDXX · Health Care Equipment
$560.38
1.1%ResMed |
RMD · Health Care Equipment
$252.86
0.1%The short version
- ResMed | is the larger business, with $5.7B of revenue in fiscal 2026 against $4.3B for Idexx Laboratories.
- Idexx Laboratories grew revenue faster (10.4%, against 9.9%).
- ResMed | kept more of each dollar of sales as operating profit (33.4% operating margin, against 31.6% operating margin).
- ResMed | turned more of its sales into free cash flow (29.2% FCF margin, against 24.6% FCF margin).
- Idexx Laboratories earned a higher return on the capital invested in it (57.3%, against 26.7%).
- Investors pay more for each dollar of Idexx Laboratories’s earnings: a P/E of 39.4x against 24.2x for ResMed |.
| Latest fiscal year | IDXX · FY25 | RMD · FY26 |
|---|---|---|
| Size | ||
| Market cap | $44.4B | $36.9B |
| Revenue | $4.3B | $5.7B |
| Free cash flow | $1.1B | $1.6B |
| Net income | $1.1B | $1.5B |
| Growth | ||
| Revenue growth | 10.4% | 9.9% |
| 5-year growth | 9.7% | 12.1% |
| Share count change | −2.7% | −0.9% |
| Profitability | ||
| Gross margin | 61.8% | 61.1% |
| Operating margin | 31.6% | 33.4% |
| Net margin | 24.6% | 26.9% |
| FCF margin | 24.6% | 29.2% |
| Return on capital | 57.3% | 26.7% |
| Return on equity | 66.2% | 24.3% |
| Balance sheet | ||
| Net debt | $270M | −$810M |
| Net debt / EBITDA | 0.2x | −0.4x |
| Dividends and buybacks | $1.2B | $1.0B |
| Valuation & quality | ||
| P/E | 39.4x | 24.2x |
| Piotroski F-score | 8 | 6 |
FY17
IDXX $2.0B
RMD $2.1B
FY18
IDXX $2.2B
RMD $2.3B
FY19
IDXX $2.4B
RMD $2.6B
FY20
IDXX $2.7B
RMD $3.0B
FY21
IDXX $3.2B
RMD $3.2B
FY22
IDXX $3.4B
RMD $3.6B
FY23
IDXX $3.7B
RMD $4.2B
FY24
IDXX $3.9B
RMD $4.7B
FY25
IDXX $4.3B
RMD $5.1B
FY26
IDXX —
RMD $5.7B
IDXX
RMD
FY17
IDXX 21.0%
RMD 20.6%
FY18
IDXX 22.2%
RMD 23.2%
FY19
IDXX 23.0%
RMD 22.2%
FY20
IDXX 25.7%
RMD 27.4%
FY21
IDXX 29.0%
RMD 28.3%
FY22
IDXX 26.7%
RMD 28.0%
FY23
IDXX 30.0%
RMD 26.8%
FY24
IDXX 29.0%
RMD 28.2%
FY25
IDXX 31.6%
RMD 32.8%
FY26
IDXX —
RMD 33.4%
IDXX
RMD
FY17
IDXX $299M
RMD $352M
FY18
IDXX $284M
RMD $442M
FY19
IDXX $304M
RMD $390M
FY20
IDXX $541M
RMD $707M
FY21
IDXX $636M
RMD $634M
FY22
IDXX $394M
RMD $216M
FY23
IDXX $773M
RMD $574M
FY24
IDXX $808M
RMD $1.3B
FY25
IDXX $1.1B
RMD $1.7B
FY26
IDXX —
RMD $1.6B
IDXX
RMD
FY17
IDXX —
RMD —
FY18
IDXX 147.3%
RMD —
FY19
IDXX 72.1%
RMD 16.9%
FY20
IDXX 62.8%
RMD 21.4%
FY21
IDXX 60.2%
RMD 15.0%
FY22
IDXX 53.3%
RMD 22.8%
FY23
IDXX 58.4%
RMD 20.0%
FY24
IDXX 49.4%
RMD 20.0%
FY25
IDXX 57.3%
RMD 26.2%
FY26
IDXX —
RMD 26.7%
IDXX
RMD
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.